Opinion|Videos|February 7, 2025
Navigating CLL Treatment Choices
Panelists discuss the factors considered when selecting between BTK inhibitors and venetoclax plus obinutuzumab for chronic lymphocytic leukemia (CLL), the considerations for choosing among acalabrutinib, zanubrutinib, and ibrutinib, and the role of cytotoxic chemotherapy in the treatment of CLL in the era of targeted therapies.
Advertisement
Episodes in this series
- What factors do you consider when selecting between BTK inhibitors and venetoclax plus obinutuzumab for CLL?
- If selecting a BTK inhibitor, what factors do you consider when selecting among acalabrutinib, zanubrutinib, and ibrutinib?
- With the availability of targeted therapies, what role does cytotoxic chemotherapy play in the treatment of CLL?
Advertisement
Related to this article
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
This pilot study found that machine learning predicted post acute facility care (PAC) needs with 85% accuracy, demonstrating its feasibility and potential to help prioritize rehabilitation consultations early in hospitalization.
New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.
Real-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per Cardinal Health review.
Women with endometriosis have a 46% higher type 2 diabetes risk, highest among premenopausal, non-obese women, study finds.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations
4
Across the US, Obesity Care Still Lacks an Owner
5